Joe Lyssikatos

Biological Characterization of ARRY-142886 (AZD6244), a Potent, Highly Selective Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor

Tammie C. Yeh, Vivienne Marsh, Bryan A. Bernat et al. · Clinical Cancer Research · 2007 · 583 citations · Full text

Medicine, Oncology, Pharmacology +14

Cyclic homopentapeptides 1. Analogs of tuberactinomycins and capreomycin with activity against vancomycin-resistant enterococci and Pasteurella

John P. Dirlam, ANNETTE M. BELTON, N. C. BIRSNER et al. · Bioorganic & Medicinal Chemistry Letters · 1997 · 22 citations

Life Sciences, Medicinal Chemistry, Microbiology +12

Abstract #1795: In Vitro and in vivo activity of ARRY-380: A potent, small molecule inhibitor of ErbB2.

Tracy Pheneger, Karyn Bouhana, Deborah Anderson et al. · Cancer Research · 2009 · 21 citations

Medicine, Oncology, Pharmacology +17

Preclinical development of ARRY-142886, a potent and selective MEK inhibitor

Eli Wallace, Tammie C. Yeh, Joe Lyssikatos et al. · Cancer Research · 2004 · 18 citations

Medicine, Cancer Biology, Pharmacology +15

Cyclic homopentapeptides 3. Synthetic modifications to the capreomycins and tuberactinomycins: Compounds with activity against methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci

R. G. II LINDE, N. C. BIRSNER, R.Y. Chandrasekaran et al. · Bioorganic & Medicinal Chemistry Letters · 1997 · 16 citations

Pharmacy, Medicinal Chemistry, Pharmacology +13